{"abstract":"The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Kyverna Therapeutics, Inc. (\"Kyverna\"), a company located in Emeryville, California, the United States of America.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/02/13/2026-02907.html","cfr_references":[],"citation":"91 FR 6863","comment_url":null,"comments_close_on":"2026-03-02","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 2, 2026 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2026-02907","effective_on":null,"end_page":6864,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/02/13/2026-02907.xml","html_url":"https://www.federalregister.gov/documents/2026/02/13/2026-02907/prospective-grant-of-an-exclusive-patent-license-in-vivo-manufactured-anti-cd19-chimeric-antigen","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-02907?publication_date=2026-02-13","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-02-13/2026-02907/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":231,"last_updated":"2026-08-26 02:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-13/pdf/2026-02907.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-02907.pdf?1770903914","publication_date":"2026-02-13","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/02/13/2026-02907.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2026-02-13T09:14:55Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":6863,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases","toc_doc":"In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases","toc_subject":"Licenses; Exemptions, Applications, Amendments, etc.","topics":[],"type":"Notice","volume":91}